Date: Tuesday, August 12, 2025
Time: 2:00 PM Singapore Time (1 hour)
An on-demand version of this webinar will be available after the live event using the same link. Register now and access the webinar at your convenience.
https://event.on24.com/wcc/r/4999455/4269F560A6A7EA7A935AD36EF0AD4828?partnerref=everyonesocial&es_id=300744905c
Summary
Join us to uncover how leading biomanufacturers are intensifying upstream processes from cell line development (CLD) through to process development (PD). This session highlights best practices, tools, and a real-world case study from CDMO, Mycenax Inc., showing how to accelerate timelines, optimize productivity, and maintain product quality—without increasing risk.
In this webinar, you will learn:
- Identify key factors driving upstream process intensification from CLD to PD
- Apply lessons from real-world industry case studies
- Recognize common challenges and risk factors in intensified upstream processing
- Implement best practices in upstream process intensification
Agenda:
- Key Drivers of Process Intensification
- Understand the critical factors for successful scale-up from CLD to PD, with a focus on maintaining robust productivity and product quality. (Janice Tan, Merck KGaA, Darmstadt, Germany)
- Case Studies in Process Intensification
- Learn from real-world examples demonstrating proof of concept in intensified upstream processes. (Jih-Huong Guo, Mycenax)
- Overcoming Challenges in Intensified Upstream Processing
- Gain insights into common obstacles, risk mitigation strategies, key takeaways and practical considerations for successful implementation. (Jih-Huong Guo, Mycenax)
- Live Q&A
- Engage with our experts during a live question-and-answer session.
Speakers
Jih-Huong Guo Mycenax Senior Cell PD Manager
Jih-Huong Guo, Senior Manager of Cell Process Development at Mycenax Biotech, has over 15 years of experience in the CRO and CDMO industry, with deep expertise in cell line development, upstream process optimization, and technology transfer for protein therapeutics. He previously led upstream development teams at TPG Biologics and Lumosa Therapeutics before joining Mycenax, where he now oversees a team of 20 scientists specializing in mammalian cell-based bioprocess development.
Since 2020, Jih-Huong has successfully led the development of multiple high-efficiency production processes, including increasing cell productivity from 2 g/L to 9 g/L and establishing a robust perfusion platform for unstable proteins. He continues to contribute to the advancement of protein drug process technologies and supports Mycenax in delivering reliable, high-quality CDMO services to clients worldwide.
Janice Tan Upstream MSAT Manager
Janice Tan heads the Upstream MSAT (Manufcaturing Sciences & Technology) team in Asia Pacific excluding China. She and her team are responsible for providing application and technical consultation on upstream bioprocesses; presenting holistic and innovative upstream solutions to customers. Prior to joining Merck, she was involved in developing customized media and feed formulations, and applying multi-omics technologies for cell line engineering, media and process development. Janice received her Ph.D. in Biochemistry from the National University of Singapore.
Rain Lee (Moderator) Regional Strategy Execution Manager & Technical Application Consultant, Upstream APeC
Rain Lee is a dynamic professional with over 9 years of experience in the chemistry, life science, and biopharmaceutical industries. In her dual role as Regional Strategy Execution Manager and Technical Application Consultant, she excels in developing and implementing GTM strategic plans for upstream bioprocessing innovations across APAC (excluding China). With a keen focus on market trends and customer needs, Rain leverages her technical expertise to help clients accelerate molecule development to the clinical phase and beyond, ensuring they stay ahead in the industry.
Date: Tuesday, August 12, 2025
Time: 2:00 PM Singapore Time (1 hour)
An on-demand version of this webinar will be available after the live event using the same link. Register now and access the webinar at your convenience.
https://event.on24.com/wcc/r/4999455/4269F560A6A7EA7A935AD36EF0AD4828?partnerref=everyonesocial&es_id=300744905c
Summary
Join us to uncover how leading biomanufacturers are intensifying upstream processes from cell line development (CLD) through to process development (PD). This session highlights best practices, tools, and a real-world case study from CDMO, Mycenax Inc., showing how to accelerate timelines, optimize productivity, and maintain product quality—without increasing risk.
In this webinar, you will learn:
- Identify key factors driving upstream process intensification from CLD to PD
- Apply lessons from real-world industry case studies
- Recognize common challenges and risk factors in intensified upstream processing
- Implement best practices in upstream process intensification
Agenda:
- Key Drivers of Process Intensification
- Understand the critical factors for successful scale-up from CLD to PD, with a focus on maintaining robust productivity and product quality. (Janice Tan, Merck KGaA, Darmstadt, Germany)
- Case Studies in Process Intensification
- Learn from real-world examples demonstrating proof of concept in intensified upstream processes. (Jih-Huong Guo, Mycenax)
- Overcoming Challenges in Intensified Upstream Processing
- Gain insights into common obstacles, risk mitigation strategies, key takeaways and practical considerations for successful implementation. (Jih-Huong Guo, Mycenax)
- Live Q&A
- Engage with our experts during a live question-and-answer session.
Speakers
Jih-Huong Guo Mycenax Senior Cell PD Manager
Jih-Huong Guo, Senior Manager of Cell Process Development at Mycenax Biotech, has over 15 years of experience in the CRO and CDMO industry, with deep expertise in cell line development, upstream process optimization, and technology transfer for protein therapeutics. He previously led upstream development teams at TPG Biologics and Lumosa Therapeutics before joining Mycenax, where he now oversees a team of 20 scientists specializing in mammalian cell-based bioprocess development.
Since 2020, Jih-Huong has successfully led the development of multiple high-efficiency production processes, including increasing cell productivity from 2 g/L to 9 g/L and establishing a robust perfusion platform for unstable proteins. He continues to contribute to the advancement of protein drug process technologies and supports Mycenax in delivering reliable, high-quality CDMO services to clients worldwide.
Janice Tan Upstream MSAT Manager
Janice Tan heads the Upstream MSAT (Manufcaturing Sciences & Technology) team in Asia Pacific excluding China. She and her team are responsible for providing application and technical consultation on upstream bioprocesses; presenting holistic and innovative upstream solutions to customers. Prior to joining Merck, she was involved in developing customized media and feed formulations, and applying multi-omics technologies for cell line engineering, media and process development. Janice received her Ph.D. in Biochemistry from the National University of Singapore.
Rain Lee (Moderator) Regional Strategy Execution Manager & Technical Application Consultant, Upstream APeC
Rain Lee is a dynamic professional with over 9 years of experience in the chemistry, life science, and biopharmaceutical industries. In her dual role as Regional Strategy Execution Manager and Technical Application Consultant, she excels in developing and implementing GTM strategic plans for upstream bioprocessing innovations across APAC (excluding China). With a keen focus on market trends and customer needs, Rain leverages her technical expertise to help clients accelerate molecule development to the clinical phase and beyond, ensuring they stay ahead in the industry.
